Related Experiment Videos

Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis

Peter Gaede1, Oluf Pedersen

  • 1Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, Copenhagen, Denmark. oluf@steno.dk

Diabetes
|November 25, 2004
PubMed

Insights

Intensive multifactorial treatment significantly reduced cardiovascular events and complications in type 2 diabetes patients. This integrated therapy approach, targeting multiple risk factors, offers substantial long-term benefits for diabetes management.

Area of Science:

  • Endocrinology
  • Cardiology
  • Nephrology

Background:

  • Type 2 diabetes presents a significant macro- and microvascular burden.
  • Previous trials show benefits from targeting individual risk factors like hyperglycemia and hypertension.
  • Current guidelines advocate for a multipronged treatment approach with ambitious targets.

Purpose of the Study:

  • To evaluate the long-term outcomes of intensive integrated therapy in type 2 diabetes.
  • To assess the impact of multifactorial intervention on cardiovascular events and diabetic complications.

Main Methods:

  • The Steno-2 Study investigated intensive versus conventional multifactorial treatment.
  • Intervention involved targeting hyperglycemia, dyslipidemia, hypertension, and other risk factors.
  • Follow-up duration averaged 7.8 years.

Main Results:

  • Intensive intervention reduced cardiovascular events by approximately 50%.
  • Significant reductions were observed in nephropathy, retinopathy, and autonomic neuropathy.
  • Compared to conventional treatment, intensive therapy demonstrated major long-term benefits.

Conclusions:

  • Intensive integrated therapy is highly effective in reducing cardiovascular and microvascular complications in type 2 diabetes.
  • The findings support the widespread adoption of aggressive, multifactorial treatment strategies.
  • Translating trial experiences into clinical practice is crucial for improving patient outcomes.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...